Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post on LinkedIn:
“In EGFR mutant NSCLC, concurrent EGFR amplification – which is assessed by many standard NGS panels – is not an uncommon finding. However, its clinical significance is unclear.
Now published in American Association for Cancer Research Clinical Cancer Research, our study tried to shed light on these tumors.”
Title: Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib
Authors: Alessandro Di Federico, Federica Pecci, Mark Jeng, Marianna Peroni, Daniele Marinelli, Alessandro Leonetti, Sara Stumpo, Francesco Mantuano, Irene Zannini, Eleonora Gariazzo, Maisam Makarem, Amanda Pupo, Francesca Lo Bianco, Andrea De Giglio, Dario de Biase, Annalisa Altimari, Elisa Gruppioni, Roberta Minari, Michela Verzè, Matteo Repetto, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Lorenza Landi, Maristella Giammaruco, Stefano Scalera, Laura Cipriani, Marcello Maugeri-Saccà, Nicola Calonaci, Giulio Caravagna, Biagio Ricciuti, Lynette M. Sholl, Soo Ryum Yang, Jaclyn LoPiccolo, Julia K. Rotow, Mark M. Awad, Federico Cappuzzo, Marcello Tiseo, Helena A. Yu, Pasi A. Jänne, Andrea Ardizzoni
Read the full article.
Other articles featuring Alessandro Di Federico on OncoDaily.